Cargando…
S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428371/ http://dx.doi.org/10.1097/01.HS9.0000967308.47141.6f |
| _version_ | 1785090452905525248 |
|---|---|
| author | Einsele, Hermann Yong, Kwee Harrison, Simon Mateos, Maria-Victoria Moreau, Philippe van de Donk, Niels W.C.J. Sidana, Surbhi Popat, Rakesh Lendvai, Nikoletta Lonardi, Carolina Slaughter, Ana Schecter, Jordan LI, Katherine Zudaire, Enrique Chen, Diana Gilbert, Jane Yeh, Tzu-Min Pacaud, Lida Patel, Nitin Dhakal, Binod San Miguel, Jesús |
| author_facet | Einsele, Hermann Yong, Kwee Harrison, Simon Mateos, Maria-Victoria Moreau, Philippe van de Donk, Niels W.C.J. Sidana, Surbhi Popat, Rakesh Lendvai, Nikoletta Lonardi, Carolina Slaughter, Ana Schecter, Jordan LI, Katherine Zudaire, Enrique Chen, Diana Gilbert, Jane Yeh, Tzu-Min Pacaud, Lida Patel, Nitin Dhakal, Binod San Miguel, Jesús |
| author_sort | Einsele, Hermann |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428371 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283712023-08-17 S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA Einsele, Hermann Yong, Kwee Harrison, Simon Mateos, Maria-Victoria Moreau, Philippe van de Donk, Niels W.C.J. Sidana, Surbhi Popat, Rakesh Lendvai, Nikoletta Lonardi, Carolina Slaughter, Ana Schecter, Jordan LI, Katherine Zudaire, Enrique Chen, Diana Gilbert, Jane Yeh, Tzu-Min Pacaud, Lida Patel, Nitin Dhakal, Binod San Miguel, Jesús Hemasphere Plenary Abstracts Session Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428371/ http://dx.doi.org/10.1097/01.HS9.0000967308.47141.6f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Plenary Abstracts Session Einsele, Hermann Yong, Kwee Harrison, Simon Mateos, Maria-Victoria Moreau, Philippe van de Donk, Niels W.C.J. Sidana, Surbhi Popat, Rakesh Lendvai, Nikoletta Lonardi, Carolina Slaughter, Ana Schecter, Jordan LI, Katherine Zudaire, Enrique Chen, Diana Gilbert, Jane Yeh, Tzu-Min Pacaud, Lida Patel, Nitin Dhakal, Binod San Miguel, Jesús S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title | S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title_full | S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title_short | S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA |
| title_sort | s100: first phase 3 results from cartitude-4: cilta-cel versus standard of care (pvd or dpd) in lenalidomide-refractory multiple myeloma |
| topic | Plenary Abstracts Session |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428371/ http://dx.doi.org/10.1097/01.HS9.0000967308.47141.6f |
| work_keys_str_mv | AT einselehermann s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT yongkwee s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT harrisonsimon s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT mateosmariavictoria s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT moreauphilippe s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT vandedonknielswcj s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT sidanasurbhi s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT popatrakesh s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT lendvainikoletta s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT lonardicarolina s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT slaughterana s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT schecterjordan s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT likatherine s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT zudaireenrique s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT chendiana s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT gilbertjane s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT yehtzumin s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT pacaudlida s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT patelnitin s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT dhakalbinod s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma AT sanmigueljesus s100firstphase3resultsfromcartitude4ciltacelversusstandardofcarepvdordpdinlenalidomiderefractorymultiplemyeloma |